EGFR and breast cancer: The anti-EGFR aptamer [33] induces selective apoptotic cell death and, upon structural optimization [the use of 2′-O-methyl (2′-OMe) units], its human serum stability and toxic potential are increased in breast cancer, liver cancer, and malignant glioblastoma cells [34].